Clinical Trial Update: Erlotinib and Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of One Chemotherapy Regimen [Phase 2]

View source ↗

Summary

This document provides a Phase 2 trial update on the combination of erlotinib and docetaxel in patients with locally advanced or metastatic non-small cell lung …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Hospital Arnau de Vilanova | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN